Melanoma
📧 Sign up to get email alerts when something new happens for Melanoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-02-24Clinical Trial Update: Using Artificial Intelligence to Help Doctors Identify Different Skin Conditions and Improve Patient Care
A completed clinical trial explores using artificial intelligence to help doctors identify skin conditions, including dermatitis and melanom…
-
CLINICAL_TRIALS research · 2026-02-24Clinical Trial Update: A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies [Phase 1, Phase 2]
This clinical trial update describes a Phase 1/2 study evaluating the safety and tolerability of TransCon IL-2 β/γ alone or in combination w…
-
CLINICAL_TRIALS research · 2026-02-24Clinical Trial Update: Neoadj Admin Autologous Tumor Infiltrating Lymphocytes & Pembrolizumab for Treatment of Adv Melanoma Patients [Phase 1]
A Phase 1 trial evaluating neoadjuvant autologous tumor-infiltrating lymphocytes combined with pembrolizumab for locally advanced and metast…
-
CLINICAL_TRIALS research · 2026-02-23Clinical Trial Update: MySmartSkin Online Skin Self-exam Intervention for Melanoma Survivors [NA]
Rutgers-led trial evaluating the MySmartSkin online skin self-exam intervention for melanoma survivors is currently recruiting.
-
CLINICAL_TRIALS research · 2026-02-20Clinical Trial Update: A Study of Dapansutrile Plus Pembrolizumab in Patients With PD-1 Refractory Advanced Melanoma [Phase 1, Phase 2]
Clinical trial update for a phase 1/2 study of Dapansutrile plus pembrolizumab in PD-1 refractory advanced melanoma; the trial is currently …
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-02-20Clinical Trial Update: Circulating Tumor DNA (ctDNA) for Early Treatment Response Assessment of Solid Tumors
Clinical trial evaluating circulating tumor DNA as an early biomarker to assess treatment response across multiple solid tumors; currently r…
-
CLINICAL_TRIALS research · 2026-02-20Clinical Trial Update: Immunotherapy Efficacy and PD-L1 as a Predictive Biomarker in Metastatic Melanoma in Slovenia [NA]
A clinical trial in Slovenia is evaluating immunotherapy efficacy and PD-L1 as a predictive biomarker for metastatic melanoma; the study is …
-
CLINICAL_TRIALS research · 2026-02-20Clinical Trial Update: The Florida ASCENT Study [NA]
The Florida ASCENT Study, sponsored by the University of Florida, is currently recruiting and investigates cancer outcomes in the context of…
-
CLINICAL_TRIALS trial_result · 2026-02-19Clinical Trial Update: Effectiveness and Safety of Dabrafenib in Combination With Trametinib as Adjuvant Treatment for Chinese Patients With Stage III BRAF V600 Mutation-positive Melanoma After Complete Resection
This clinical trial update assesses the effectiveness and safety of combining dabrafenib with trametinib as adjuvant therapy for Chinese pat…
-
CLINICAL_TRIALS research · 2026-02-19Clinical Trial Update: A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head) [Phase 3]
Phase 3 study evaluating combinations of anti-LAG-3 and anti-PD-1 antibodies in adults with advanced or metastatic melanoma; the trial is cu…
-
CLINICAL_TRIALS research · 2026-02-19Clinical Trial Update: A Study of Tumor Imaging With Multispectral Optoacoustic Tomography
This clinical trial update describes a study evaluating tumor imaging with Multispectral Optoacoustic Tomography (MSOT) at Memorial Sloan Ke…
-
CLINICAL_TRIALS trial_result · 2026-02-18Clinical Trial Update: Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma [Phase 3]
Phase 3 clinical trial evaluating two sequencing strategies for BRAFV600-mutant stage III–IV melanoma: dabrafenib plus trametinib followed b…
-
CLINICAL_TRIALS research · 2026-02-18Clinical Trial Update: A Phase 1/2 Study of KSQ-001EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate the SOCS1 Gene, in Patients With Select Advanced Solid Tumors [Phase 1, Phase 2]
Phase 1/2 study of KSQ-001EX, autologous tumor infiltrating lymphocytes engineered to inactivate SOCS1, being evaluated in select advanced s…
-
CLINICAL_TRIALS research · 2026-02-18Clinical Trial Update: EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors [Phase 1, Phase 2]
Clinical Trial Update on an ongoing Phase 1/2 study of allogeneic NK cells (EBNK-001) with low-dose interleukin-15, with or without pembroli…
-
CLINICAL_TRIALS research · 2026-02-18Clinical Trial Update: Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors [Phase 1, Phase 2]
This clinical trial update details a biomarker-guided allogeneic CAR-NK cell therapy using single-target or dual-target constructs for advan…
-
CLINICAL_TRIALS research · 2026-02-18Clinical Trial Update: BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20) [Phase 1, Phase 2]
This trial investigates BI-1808 as a single agent and in combination with pembrolizumab (Keytruda) for advanced malignancies, including ovar…
-
CLINICAL_TRIALS research · 2026-02-17Clinical Trial Update: A Study of IO102/IO103, Nivolumab, and Relatlimab in People With Melanoma [Phase 2]
A Phase 2 clinical trial evaluating IO102/IO103 in combination with nivolumab and relatlimab for melanoma is currently active but not recrui…
-
CLINICAL_TRIALS research · 2026-02-17Clinical Trial Update: INTEGRATIVE "MULTI-OMICS" AND FUNCTIONAL PLATFORM FOR THE COMPLETE DIAGNOSTIC CHARACTERIZATION OF TUMORS: THE ITALIAN TUMOR CHEMOGENOMIC PROFILER (IT-TCP) [NA]
A clinical trial update describing the Italian Tumor Chemogenomic Profiler (IT-TCP), an integrative multi-omics and functional platform to d…
-
CLINICAL_TRIALS research · 2026-02-17Clinical Trial Update: Efficacy of First-Line Immunotherapy in Metastatic Melanoma in Slovenia and Identification of Predictive Biomarkers [NA]
A clinical trial investigating the efficacy of first-line immunotherapy for metastatic melanoma and identifying predictive biomarkers, curre…
-
CLINICAL_TRIALS research · 2026-02-17Clinical Trial Update: Nodal Radiation Therapy for Sentinel Lymph Node Positive Melanoma [Phase 2]
This clinical trial update notes a Phase 2 study investigating nodal radiation therapy for sentinel lymph node-positive melanoma, currently …
-
CLINICAL_TRIALS research · 2026-02-17Clinical Trial Update: Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal Cell Carcinoma [Phase 2]
Phase II trial evaluating a combination of anti-PD-1 therapy and aldesleukin (IL-2) for metastatic melanoma and metastatic renal cell carcin…
-
CLINICAL_TRIALS research · 2026-02-17Clinical Trial Update: A Storage Facility for Tissues Obtained From Patients With Malignant Melanoma
Ongoing recruitment for a study at Ohio State University Comprehensive Cancer Center that involves collecting and storing tissue samples fro…
-
CLINICAL_TRIALS trial_result · 2026-02-13Clinical Trial Update: A Phase I Clinical Study to Evaluate the PK Profile, Efficacy, Safety and Immunogenicity of HLX17 vs. Keytruda® in Multiple Resected Solid Tumors [Phase 1]
Phase I trial comparing HLX17 to Keytruda in multiple solid tumors to evaluate pharmacokinetics, preliminary efficacy, safety, and immunogen…
-
CLINICAL_TRIALS research · 2026-02-13Clinical Trial Update: Nilotinib Plus Dabrafenib/Trametinib or Encorafenib/Binimetinib in Metastatic Melanoma [Phase 1]
A phase 1 trial investigating Nilotinib in combination with either Dabrafenib/Trametinib or Encorafenib/Binimetinib in metastatic melanoma w…
-
CLINICAL_TRIALS research · 2026-02-12Clinical Trial Update: Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study [Phase 2]
A Phase 2 trial (The Knight SHIFT Study) is comparing morning versus afternoon administration of immunotherapy for advanced or metastatic so…